EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Innovative approaches for vaccine trials as a key component of pandemic preparedness – a white paper

Ullrich Bethe, Zoi D Pana, Christian Drosten, Herman Goossens, Franz König, Arnaud Marchant, Geert Molenberghs, Martin Posch, Pierre Van Damme, Oliver A Cornely

Infection · 2024

DOI: 10.1007/s15010-024-02347-1 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Infection, 2024. Verfasst von Ullrich Bethe und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Faculty of Medicin…. Hauptthemen laut MEDLINE: Pandemics, Clinical Trials as Topic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Köln.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

WHO postulates the application of adaptive design features in the global clinical trial ecosystem. However, the adaptive platform trial (APT) methodology has not been widely adopted in clinical research on vaccines.

Methods

The VACCELERATE Consortium organized a two-day workshop to discuss the applicability of APT methodology in vaccine trials under non-pandemic as well as pandemic conditions. Core aspects of the discussions are summarized in this article.

Results

An “ever-warm” APT appears ideally suited to improve efficiency and speed of vaccine research. Continuous learning based on accumulating APT trial data allows for pre-planned adaptations during its course. Given the relative design complexity, alignment of all stakeholders at all stages of an APT is central. Vaccine trial modelling is crucial, both before and in a pandemic emergency. Various inferential paradigms are possible (frequentist, likelihood, or Bayesian). The focus in the interpandemic interval may be on research gaps left by industry trials. For activation in emergency, template Disease X protocols of syndromal design for pathogens yet unknown need to be stockpiled and updated regularly. Governance of a vaccine APT should be fully integrated into supranational pandemic response mechanisms.

Discussion

A broad range of adaptive features can be applied in platform trials on vaccines. Faster knowledge generation comes with increased complexity of trial design. Design complexity should not preclude simple execution at trial sites. Continuously generated evidence represents a return on investment that will garner societal support for sustainable funding. Adaptive design features will naturally find their way into platform trials on vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PandemicsClinical Trials as TopicHumansVaccinesResearch DesignCOVID-19Pandemic PreparednessAdaptive Clinical Trials as Topic

Stichwörter der Autor:innen

Adaptive platform trialBayesianConcurrent controlsEnrichmentFrequentistInterpandemic intervalModelling pandemic preparednessPreventionRandomized clinical trialResponse-adaptive randomizationSimulationStakeholdersTrial designVACCELERATEVaccines

Substanzen

Vaccines

Autor:innen und Institutionen

  • Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Herderstrass…
  • Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Department I of Internal Medicine, Faculty of Medicine, University Hospital Cologne, University…
  • Partner Site Bonn-Cologne, German Centre for Infection Research (DZIF), Cologne, Germany.
  • Medical School, European University of Cyprus, Nicosia, Cyprus.
  • Institute of Virology, Charité Universitätsmedizin Berlin, Berlin, Germany.
  • Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute and Biobank Antwerp, University of Antwerp, Wilrijk, Belgium.

Förderung

  • Universitätsklinikum Köln

Zitieren

APA

Bethe, U., Pana, Z. D., Drosten, C., Goossens, H., König, F., Marchant, A., Molenberghs, G., Posch, M., Van Damme, P., & Cornely, O. A. (2024). Innovative approaches for vaccine trials as a key component of pandemic preparedness – a white paper. Infection. https://doi.org/10.1007/s15010-024-02347-1

Vancouver

Bethe U, Pana ZD, Drosten C, Goossens H, König F, Marchant A, et al. Innovative approaches for vaccine trials as a key component of pandemic preparedness – a white paper. Infection. 2024. doi:10.1007/s15010-024-02347-1

BibTeX
@article{Bethe2024,
  author = {Bethe, Ullrich and Pana, Zoi D and Drosten, Christian and Goossens, Herman and König, Franz and Marchant, Arnaud and Molenberghs, Geert and Posch, Martin and Van Damme, Pierre and Cornely, Oliver A},
  title = {Innovative approaches for vaccine trials as a key component of pandemic preparedness – a white paper},
  journal = {Infection},
  year = {2024},
  doi = {10.1007/s15010-024-02347-1}
}
Kostenlos starten →